Latest / From Our Neurons to Yours
The FDA's psychedelic sea-change: what accelerated clinical trials for psilocybin, methylone, and ibogaine mean for mental health and neuroscience research | Boris Heifets
Last month we saw a big shift in the federal government’s approach to psychedelic medicine.
Specifically, following an executive order by President Trump, the FDA announced it is fast-tracking its review of several clinical trials of psychedelic drugs for patients with mental health disorders. The executive order also directed more funds towards psychedelic research and a review of psychedelics’ status as highly restricted Schedule 1 substances.
To help us understand what all this means for the future of psychedelic medicine and the neuroscience of psychedelics, we’re joined by Boris Heifets…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.